A patient's pathway: Alzheimer's **Disease**

We are entering an era filled with hope in the fight against Alzheimer's Disease. New therapies that target amyloid, a protein that builds up in the brain and disrupts neuron function, could help to slow down progression of early Alzheimer's Disease.

GE HealthCare is well positioned to support the patient journey with its products and solutions — from diagnosis through to therapy planning and monitoring.



Opportunity with access to amyloid targeting therapies



Patient history, family history, cognitive history, physical examination





Patient history, family history, cognitive history, physical examination



Neuropsychological tests or neurocognitive tests



Genetic risk assessment



Potential blood biomarker tests (to check for certain genes, proteins, or other molecules that may be relevant for diagnosis)



Neuropsychological

tests or

neurocognitive

tests



Genetic risk assessment



Potential blood biomarker tests (to check for certain genes, proteins, or other molecules that may be relevant for diagnosis)

IN SELECTED CASES



Full

clinical

workup

with a

specialist











Potential **Potential**

IN SELECTED CASES

lumbar puncture to evaluate cerebrospinal fluid (CSF) and assess other biomarkers relevant to the diagnosis



Full clinical workup with a specialist



MRI to capture initial baseline image of the brain before treatment. CT may be performed

if structural

changes to

the brain are

suspected



Positron Emission Tomography (PET) to evaluate amyloid plaque* in


Potential

the brain *abnormal accumulations of protein fragments that occur in the brain of individuals with certain neurodegenerative diseases

Potential lumbar puncture to evaluate cerebrospinal fluid (CSF) and assess other biomarkers relevant to

the diagnosis





CT and MRI

Positron Emission Tomography (PET) to evaluate amyloid plaque* in the brain *abnormal accumulations of protein

fragments that occur in the brain of individuals

with certain

neurodegenerative

diseases







Amyloid targeting therapy infusion to reduce amyloid deposits in the brain — which could delay progression of the disease; There is an option of switching to subcutaneous therapies after the first 18 months²



Physical





Multiple prescription drugs to help manage symptoms of Alzheimer's Disease without addressing underlying pathology or changing course of the disease




Physical activity, memory and orientation exercises, music- and art-based therapies, and many others1





activity, memory and orientation exercises, music- and art-based therapies, and many others1



help manage symptoms of Alzheimer's Disease the need for medication may vary depending

on the case



History and neuropsychological

test to assess cognitive functions





History and neuropsychological

test to assess cognitive functions



MRI to monitor potential side effects due to treatment and ensure continued safety of patient





Potentially PET — Some therapies could potentially be discontinued once amyloid has been removed to minimal levels on amyloid PET imaging



Digital solutions

Could help with risk assessment, brain amyloid PET quantification, treatment decisions and workflow management

Did you know

11% About 1 in 9 people age 65 and older (11%) has Alzheimer's

74% of dementia caregivers say that they are concerned about maintaining their own health since becoming a caregiver³

27%-35%

New therapies have shown to decrease the progression of early Alzheimer's Disease by 27%-35% after 18 months of treatment.^{4,5}

SOURCES

- 1. https://www.alz.org/alzheimers-dementia/facts-figures. Consulted in July 2025.
- 2. https://www.eisai.com/news/2025/news202559.html. Consulted in October 2025. 3. https://www.alz.org/news/2024/november-national-family-caregivers-month. Consulted in July 2025.
- 4. https://www.yalemedicine.org/news/lecanemab-leqembi-new-alzheimers-drug. Consulted in July 2025. 5. https://www.sciencealert.com/major-alzheimers-trial-shows-new-drug-can-slow-disease-progression. Consulted in July 2025.

